Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group. Baden LR, et al. Among authors: michael nl. J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212. J Infect Dis. 2018. PMID: 29669026 Free PMC article. Clinical Trial.
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
Frankel SS, Steinman RM, Michael NL, Kim SR, Bhardwaj N, Pope M, Louder MK, Ehrenberg PK, Parren PW, Burton DR, Katinger H, VanCott TC, Robb ML, Birx DL, Mascola JR. Frankel SS, et al. Among authors: michael nl. J Virol. 1998 Dec;72(12):9788-94. doi: 10.1128/JVI.72.12.9788-9794.1998. J Virol. 1998. PMID: 9811714 Free PMC article.
Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, Redfield RR. Birx DL, et al. J Infect Dis. 2000 Mar;181(3):881-9. doi: 10.1086/315308. J Infect Dis. 2000. PMID: 10720508 Clinical Trial.
Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, Michael NL, Jagodzinski L, Hawkes C, Mayers D, Gilliam BL, Birx DC, Robb ML. Kim JH, et al. Among authors: michael nl. AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1021-34. doi: 10.1089/088922201300343708. AIDS Res Hum Retroviruses. 2001. PMID: 11485619
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.
Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, McKenna P, Hertogs K, Rinehart A, Larder B, Birx DL; RV-125 Centers for Education and Research on Therapeutics Study Team. Wegner SA, et al. Among authors: michael nl. Clin Infect Dis. 2004 Mar 1;38(5):723-30. doi: 10.1086/381266. Epub 2004 Feb 6. Clin Infect Dis. 2004. PMID: 14986258 Clinical Trial.
455 results